Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. markets close on Wednesday, May 7, 2025.
A conference call with analysts to discuss financial results and recent business highlights will be held on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). The event will be accessible via webcast through Alvotech's investor website, with a 90-day replay period available after the presentation.
Alvotech (NASDAQ: ALVO), un'azienda biotecnologica globale specializzata nello sviluppo di medicinali biosimilari, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025. La società pubblicherà i risultati del Q1 2025 dopo la chiusura dei mercati statunitensi, mercoledì 7 maggio 2025.
Una conference call con gli analisti per discutere i risultati finanziari e gli ultimi aggiornamenti aziendali si terrà giovedì 8 maggio 2025 alle 8:00 EDT (12:00 ora di Greenwich, 14:00 CET). L'evento sarà accessibile via webcast attraverso il sito web per gli investitori di Alvotech, con una replica disponibile per 90 giorni dopo la presentazione.
Alvotech (NASDAQ: ALVO), una compañía biotecnológica global enfocada en el desarrollo de medicamentos biosimilares, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025. La empresa publicará los resultados del Q1 2025 tras el cierre de los mercados estadounidenses el miércoles 7 de mayo de 2025.
Una llamada con analistas para discutir los resultados financieros y las novedades comerciales recientes se realizará el jueves 8 de mayo de 2025 a las 8:00 am EDT (12:00 mediodía GMT, 14:00 CET). El evento será accesible vía webcast a través del sitio web para inversores de Alvotech, con una repetición disponible durante 90 días después de la presentación.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품 개발에 주력하는 글로벌 바이오텍 기업으로, 2025년 1분기 재무 실적 발표 일정을 확정했습니다. 회사는 2025년 5월 7일 수요일 미국 시장 마감 후 1분기 2025 실적을 발표할 예정입니다.
재무 실적 및 최근 비즈니스 주요 내용을 논의하기 위한 애널리스트 대상 컨퍼런스 콜은 2025년 5월 8일 목요일 오전 8시 EDT(그리니치 표준시(GMT) 정오 12시, 중앙유럽 시간(CET) 오후 2시)에 진행됩니다. 해당 행사는 Alvotech 투자자 웹사이트를 통해 웹캐스트로 제공되며, 발표 후 90일간 다시보기 서비스가 제공됩니다.
Alvotech (NASDAQ : ALVO), une entreprise biotechnologique mondiale spécialisée dans le développement de médicaments biosimilaires, a programmé l'annonce de ses résultats financiers du premier trimestre 2025. La société publiera ses résultats du T1 2025 après la clôture des marchés américains, le mercredi 7 mai 2025.
Une conférence téléphonique avec les analystes pour discuter des résultats financiers et des faits marquants récents se tiendra le jeudi 8 mai 2025 à 8h00 EDT (12h00 GMT, 14h00 CET). L'événement sera accessible en webcast via le site des investisseurs d'Alvotech, avec une rediffusion disponible pendant 90 jours après la présentation.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen, das sich auf die Entwicklung von Biosimilars konzentriert, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 geplant. Das Unternehmen wird die Q1 2025-Ergebnisse nach Börsenschluss in den USA am Mittwoch, den 7. Mai 2025 veröffentlichen.
Eine Telefonkonferenz mit Analysten zur Besprechung der Finanzergebnisse und aktuellen Geschäftshighlights findet am Donnerstag, den 8. Mai 2025, um 8:00 Uhr EDT (12:00 Uhr GMT, 14:00 Uhr MEZ) statt. Die Veranstaltung ist über einen Webcast auf der Investorenseite von Alvotech zugänglich, mit einer 90-tägigen Wiederholungsoption nach der Präsentation.
- None.
- None.
REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public.
Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor website https://investors.alvotech.com. Links to access the webcast or sign in number for analysts is found at https://investors.alvotech.com/events/event-details/q1-2025-earnings. The webcast will also be archived and available for replay for 90 days after the event.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
FAQ
When will Alvotech (ALVO) release its Q1 2025 earnings?
What time is Alvotech's Q1 2025 earnings call?
How can I access Alvotech's Q1 2025 earnings webcast?
How long will Alvotech's Q1 2025 earnings webcast be available for replay?
